Investigational drug · Phase 2
Recombinant Human IL12
Also called: 15-PDL1B Oncolytic HSV-1, VG161, 15 Dual-Regulated Oncolytic HSV-1
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Malignant Solid Tumor, Sarcoma, Advanced Intrahepatic Cholangiocarcinoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
38
Any phase or sponsor naming "Recombinant Human IL12"
First trial start
2022
Mar 19, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Recombinant Human IL12", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignant Solid Tumor
- Sarcoma
- Advanced Intrahepatic Cholangiocarcinoma
Approved drugs for the same conditions: Sarcoma · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Recombinant Human IL12" as an intervention, largest first.
National Cancer Institute (NCI)NIH
NCT00003210 · 105 participants · Start Feb 1998 · Primary completion Nov 2003
Drug: recombinant interleukin-12 · For: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma and 14 more
Sites: Houston, Texas
- A Direct Head-to-head Comparison of Ustekinumab With Infliximab for the Treatment of Ulcerative ColitisActive, not recruiting
Helwan UniversityAcademic, hospital or other
NCT06786507 · 100 participants (planned) · Start May 15, 2025 · Primary completion Dec 12, 2027
Drug: Ustekinumab 90 mg; Infliximab · For: Ulcerative Colitis (UC)
Sites: Cairo, Egypt
Virogin Biotech Canada LtdIndustry
NCT05223816 · 97 participants (planned) · Start Jan 24, 2024 · Primary completion Oct 1, 2025
Drug: VG161; Nivolumab Injection [Opdivo] · For: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma
Sites: Phoenix, Arizona; Jacksonville, Florida; Rochester, Minnesota
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000857 · 65 participants
Drug: Interleukin-12 · For: HIV Infections
Sites: Los Angeles, California; Palo Alto, California; San Francisco, California · 16 sites in all
- Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic CancerStatus unknown
Zhejiang UniversityAcademic, hospital or other
NCT05162118 · 51 participants (planned) · Start Mar 8, 2022 · Primary completion Mar 22, 2025
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab · For: Advanced Pancreatic Cancer
Sites: Hangzhou, China
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00001906 · 50 participants · Start Apr 1999
Drug: Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants · For: Cutaneous Leishmaniasis
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT00052377 · 46 participants · Start Sep 2002 · Primary completion Jun 2005
Drug: aldesleukin; recombinant interleukin-12 · For: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma and 7 more
Sites: Philadelphia, Pennsylvania
CNBG-Virogin Biotech (Shanghai) Ltd.Industry
NCT04806464 · 44 participants (planned) · Start Mar 16, 2021 · Primary completion Mar 21, 2022
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) · For: Primary Liver Cancer
Sites: Hangzhou, China
- Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric CancerStatus unknown
CNBG-Virogin Biotech (Shanghai) Ltd.Industry
NCT06008925 · 43 participants (planned) · Start Nov 17, 2022 · Primary completion Dec 2025
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)); Nivolumab Injection · For: Metastatic Gastric Cancer
Sites: Beijing, China
- Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid TumorsActive, not recruiting
Sonnet BioTherapeuticsIndustry
NCT05352750 · 42 participants · Start Apr 20, 2022 · Primary completion Jun 30, 2026
Drug: SON-1010 · For: Advanced Solid Tumor; Soft Tissue Sarcoma Adult
Sites: Santa Monica, California
Newest research
PubMed records naming it or its code names, newest first.
- Liver-resident cellular determinants of oncolytic virotherapy in hepatocellular carcinoma: viral susceptibility and spatial immune remodeling.
Hu D, Wang Q · Front Cell Dev Biol 2026
- VG161 oncolytic virus remodels the tumor microenvironment by expanding CD3+ macrophages and enhancing antitumor immunity.
Bai F, Qin G, Li J, et al. · Cancer Lett 2026
- Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer.
Lyu L, Yi M, Chen J, et al. · Adv Sci (Weinh) 2026
- Immune reprogramming of cold tumors using TGF-β/PD-L1 bispecific antibody and armed oncolytic virus therapy.
Sun Y, Hu S, Yi M, et al. · Adv Clin Exp Med 2025
- Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies.
Shen Y, Jin X, Song W, et al. · Gut 2025
- Oncolytic virus VG161 offers new hope for refractory liver cancer.
Li J, Zhou H, Wang X, et al. · Front Oncol 2025
Also in development for Advanced Malignant Solid Tumor
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- SCTB41Phase 36 trials
Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor
- PRL3-ZUMABPhase 34 trials
Intra-IMMUSG Pte Ltd · Advanced Malignant Solid Tumor, Solid Tumor, Advanced Solid Cancers
- MHB039APhase 24 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Malignant Solid Tumor, Advanced Breast Cancer, Advanced Lung Cancer
- MHB036CPhase 23 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Breast Cancer, Advanced Malignant Solid Tumor, Advanced Lung Cancer
- PD-L1 monoclonal antibodyPhase 22 trials
Suzhou BlueHorse Therapeutics Co., Ltd. · Non-Small Cell Lung Cancer, Advanced Malignant Solid Tumor
- SCTB39-1Phase 22 trials
Sinocelltech Ltd. · Advanced Malignant Solid Tumor
- SCTB39GPhase 22 trials
Sinocelltech Ltd. · Advanced Malignant Solid Tumor, Advanced Malignant Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.